Avalo Therapeutics (AVTX) Short Interest Ratio & Short Volume → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free AVTX Stock Alerts $10.92 +0.71 (+6.95%) (As of 06/10/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Avalo Therapeutics Short Interest DataCurrent Short Interest83,100 sharesPrevious Short Interest104,300 sharesChange Vs. Previous Month-20.33%Dollar Volume Sold Short$863,409.00Short Interest Ratio0.1 Days to CoverLast Record DateMay 15, 2024Outstanding Shares1,030,000 sharesPercentage of Shares Shorted8.07%Today's Trading Volume19,990 sharesAverage Trading Volume402,966 sharesToday's Volume Vs. Average5% Short Selling Avalo Therapeutics ? Sign up to receive the latest short interest report for Avalo Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAVTX Short Interest Over TimeAVTX Days to Cover Over TimeAVTX Percentage of Float Shorted Over Time Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", Avalo Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202483,100 shares $863,409.00 -20.3%N/A0.1 $10.39 4/30/2024104,300 shares $1.79 million -32.0%N/A0.2 $17.12 4/15/2024153,400 shares $2.34 million +95.4%N/A0.2 $15.24 3/31/202478,500 shares $1.71 million +16.8%N/A0.1 $21.75 3/15/202467,200 shares $293,664.00 +10.3%N/A1.3 $4.37 2/29/202460,900 shares $268,569.00 -4.8%N/A0.7 $4.41 Get the Latest News and Ratings for AVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/202464,000 shares $304,640.00 -21.3%N/A0.7 $4.76 1/31/202481,300 shares $378,045.00 -4.0%N/A0.8 $4.65 1/15/202484,700 shares $484,484.00 +32.1%N/A0.7 $5.72 12/31/202364,100 shares $583,310.00 -99.5%N/A0.4 $9.10 12/15/202312,640,000 shares $758,400.00 +23.8%N/A0.2 $0.06 11/30/202310,210,000 shares $713,679.00 -43.7%N/A0.1 $0.07 11/15/202318,140,000 shares $1.79 million +40.8%N/A0.2 $0.10 10/31/202312,880,000 shares $1.41 million +3.5%N/A0.2 $0.11 10/15/202312,450,000 shares $1.85 million -29.1%N/A0.2 $0.15 9/30/202317,550,000 shares $2.12 million +471.7%90.2%0.3 $0.12 9/15/20233,070,000 shares $406,775.00 +220.1%15.8%0.1 $0.13 8/31/2023959,000 shares $95,900.00 +0.2%5.2%0.1 $0.10 8/15/2023957,300 shares $134,022.00 -10.5%5.2%0.2 $0.14 7/31/20231,070,000 shares $214,000.00 +20.6%5.8%0.6 $0.20 7/15/2023887,000 shares $294,572.70 +41.2%7.4%0.7 $0.33 6/30/2023628,400 shares $223,207.68 +1,528.0%5.3%0.6 $0.36 6/15/202338,600 shares $145,329.00 -9.4%0.4%0.1 $3.77 5/31/202342,600 shares $122,262.00 -2.7%0.4%0.6 $2.87 5/15/202343,800 shares $120,450.00 +17.1%0.4%0.9 $2.75 4/30/202337,400 shares $108,834.00 -23.8%0.3%1.2 $2.91 4/15/202349,100 shares $127,660.00 +172.8%0.4%1.7 $2.60 3/31/202318,000 shares $31,500.00 -3.7%0.2%0.7 $1.75 3/15/202318,700 shares $46,843.50 -24.6%0.2%1.1 $2.51 2/28/202324,800 shares $62,496.00 +30.5%0.4%1.6 $2.52 2/15/202319,000 shares $56,240.00 -32.4%0.3%1.3 $2.96 1/31/202328,100 shares $110,714.00 -30.8%0.3%1.7 $3.94 1/15/202340,600 shares $197,316.00 +17.0%0.5%2.7 $4.86 12/30/202234,700 shares $174,891.47 -15.0%0.4%2.4 $5.04 12/15/202240,800 shares $237,864.00 +9.4%0.5%3 $5.83 11/30/202237,300 shares $204,031.00 +9.1%0.4%2.3 $5.47 11/15/202234,200 shares $198,360.00 -3.1%0.4%1.7 $5.80 10/31/202235,300 shares $211,800.00 -27.5%0.4%1.1 $6.00 10/15/202248,700 shares $258,110.00 +10.9%0.6%1.4 $5.30 9/30/202243,900 shares $145,748.00 -34.1%0.5%1.2 $3.32Protect Your Bank Account Before It’s Too Late (Ad)For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself 9/15/202266,600 shares $279,054.00 +26.1%0.8%1.3 $4.19 8/31/202252,800 shares $250,800.00 -39.5%0.6%1 $4.75 8/15/202287,300 shares $467,928.00 -10.9%1.0%1.6 $5.36 7/31/202298,000 shares $352,800.00 +2.9%1.1%1.8 $3.60 7/15/202295,200 shares $437,920.00 +26.8%1.1%1.9 $4.60 6/30/202275,100 shares $450,600.00 -96.8%9.6%1.5 $6.00 6/15/20222,380,000 shares $1.09 million +10.2%2.3%4.1 $0.46 5/31/20222,160,000 shares $777,816.00 +4.4%2.0%4.8 $0.36 5/15/20222,070,000 shares $517,293.00 -0.5%2.0%4.7 $0.25 4/30/20222,080,000 shares $854,880.00 +20.9%1.9%5.2 $0.41 4/15/20221,720,000 shares $1.03 million +19.4%1.5%4.5 $0.60 3/31/20221,440,000 shares $1.04 million +2.1%1.3%2.8 $0.72 3/15/20221,410,000 shares $913,398.00 -0.7%1.3%2.7 $0.65 2/28/20221,420,000 shares $1.04 million +13.6%1.3%2.6 $0.73 2/15/20221,250,000 shares $1.13 million -17.2%1.1%2.4 $0.90 1/31/20221,510,000 shares $1.48 million -24.1%1.4%3 $0.98 1/15/20221,990,000 shares $1.99 million +28.4%1.8%3.9 $1.00 12/31/20211,550,000 shares $2.64 million No Change1.4%3.7 $1.70 AVTX Short Interest - Frequently Asked Questions What is Avalo Therapeutics' current short interest? Short interest is the volume of Avalo Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 83,100 shares of AVTX short. Learn More on Avalo Therapeutics' current short interest. Which institutional investors are shorting Avalo Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Avalo Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Avalo Therapeutics' short interest increasing or decreasing? Avalo Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 83,100 shares, a decline of 20.3% from the previous total of 104,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Avalo Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Avalo Therapeutics: Vincerx Pharma, Inc. (1.92%), GlycoMimetics, Inc. (3.63%), OncoCyte Co. (3.05%), Sol-Gel Technologies Ltd. (0.11%), Gain Therapeutics, Inc. (0.60%), Kronos Bio, Inc. (1.67%), Aadi Bioscience, Inc. (5.54%), Daré Bioscience, Inc. (0.53%), Ocuphire Pharma, Inc. (5.09%), Reviva Pharmaceuticals Holdings, Inc. (6.38%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Avalo Therapeutics stock? Short selling AVTX is an investing strategy that aims to generate trading profit from Avalo Therapeutics as its price is falling. AVTX shares are trading up $0.71 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Avalo Therapeutics? A short squeeze for Avalo Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AVTX, which in turn drives the price of the stock up even further. How often is Avalo Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AVTX, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Vincerx Pharma Short Squeeze GlycoMimetics Short Squeeze OncoCyte Short Squeeze Sol-Gel Technologies Short Squeeze Gain Therapeutics Short Squeeze Kronos Bio Short Squeeze Aadi Bioscience Short Squeeze Daré Bioscience Short Squeeze Ocuphire Pharma Short Squeeze Reviva Pharmaceuticals Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AVTX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.